Ovarian Leydig Cell Tumor and Ovarian Hyperthecosis in a Postmenopausal Woman: A Case Report and Literature Review

Medicina (Kaunas). 2023 Jun 6;59(6):1097. doi: 10.3390/medicina59061097.

Abstract

Ovarian Leydig cell tumor is a rare type of ovarian steroid cell neoplasms, presenting in only 0.1% of all ovarian tumor cases, and is generally androgen-secreting and unilateral. Although they are often malignant non-spreading tumors, which have excellent prognosis, benign ovarian Leydig cell tumors with low-risk malignancy can be also detected. Ovarian hyperthecosis is a rare non-neoplastic disorder, in most cases bilateral. Ovarian tumors and ovarian hyperthecosis are one of the main causes of hyperandrogenism in postmenopausal women, a condition strongly associated with both hormonal and metabolic changes. Here, we report a 65-year-old patient with complaints of excessive body hairiness and alopecia. The laboratory investigation showed increased levels of serum testosterone and dehydroepiandrosterone sulfate (DHEA-S). Imaging, including transvaginal ultrasound and pelvic MRI revealed the presence of two masses in the ovaries. The patient underwent a laparoscopic bilateral salpingo-oophorectomy due to the ovarian tumors unknown etiology, and histopathological examination revealed a unilateral benign left ovarian Leydig cell tumor with bilateral ovarian stromal hyperplasia and ovarian hyperthecosis. Making differential diagnosis between ovarian tumors and ovarian hyperthecosis is difficult. Bilateral salpingo-oophorectomy is the treatment of choice in postmenopausal women with benign Leydig cell ovarian tumor, as well as ovarian hyperthecosis, as it offers both a cure and diagnostic confirmation.

Keywords: hyperandrogenism; ovarian Leydig cell tumor; ovarian hyperthecosis; postmenopausal women; salpingo-oophorectomy.

Publication types

  • Review
  • Case Reports

MeSH terms

  • Aged
  • Female
  • Hirsutism / complications
  • Humans
  • Hyperandrogenism*
  • Leydig Cell Tumor* / complications
  • Leydig Cell Tumor* / diagnosis
  • Leydig Cell Tumor* / surgery
  • Male
  • Ovarian Neoplasms* / complications
  • Ovarian Neoplasms* / diagnosis
  • Ovarian Neoplasms* / pathology
  • Polycystic Ovary Syndrome* / complications
  • Postmenopause
  • Testosterone

Substances

  • Testosterone

Grants and funding

This research received no external funding.